MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INKT MiNK Therapeutics, Inc.

Not Yet Opened 05-20 16:00:00 EDT

10.72

+0.37

+3.57%

盘后10.51

-0.21-1.96%

19:03 EDT

High10.95	Low10.24	Vol36.33K
Open10.31	D1 Closing10.35	Amplitude6.86%
Mkt Cap53.23M	Tradable Cap17.98M	Total Shares4.97M
T/O386.56K	T/O Rate2.17%	Tradable Shares1.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INKT","market":"US","secType":"STK","nameCN":"MiNK Therapeutics, Inc.","latestPrice":10.72,"timestamp":1779307200000,"preClose":10.35,"halted":0,"volume":36327,"hourTrading":{"tag":"盘后","latestPrice":10.51,"preClose":10.72,"latestTime":"19:03 EDT","volume":433,"amount":4562.19,"timestamp":1779318205179,"change":-0.21,"changeRate":-0.01959,"amplitude":0.01959},"delay":0,"changeRate":0.0357487922705315,"floatShares":1677000,"shares":4965858,"eps":-2.784285,"marketStatus":"Not Yet Opened","change":0.37,"latestTime":"05-20 16:00:00 EDT","open":10.31,"high":10.95,"low":10.24,"amount":386556.34258,"amplitude":0.068599,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.784285,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779350400000},"marketStatusCode":0,"adr":0,"listingDate":1634270400000,"exchange":"NASDAQ","adjPreClose":10.35,"preHourTrading":{"tag":"盘前","latestPrice":10.39,"preClose":10.35,"latestTime":"09:27 EDT","volume":399,"amount":4151.022833999999,"timestamp":1779283670216,"change":0.04,"changeRate":0.003865,"amplitude":0.01343},"postHourTrading":{"tag":"盘后","latestPrice":10.51,"preClose":10.72,"latestTime":"19:03 EDT","volume":433,"amount":4562.19,"timestamp":1779318205179,"change":-0.21,"changeRate":-0.01959,"amplitude":0.01959},"volumeRatio":0.8435},"requestUrl":"/m/hq/s/INKT","defaultTab":"news","newsList":[{"id":"2636826153","title":"MiNK Therapeutics reports new data on agenT-797 at ATS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636826153","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636826153?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:15","pubTimestamp":1779290148,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced new clinical and translational data presented at the American Thoracic Society International Conference 2026 and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-reports-new-data-on-agent-797-at-ats-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-reports-new-data-on-agent-797-at-ats-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4161","INKT","BK4139","ATS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636826375","title":"Mink Therapeutics starts Phase 2 trial of agenT-797 in severe acute lung injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2636826375","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636826375?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:07","pubTimestamp":1779289655,"startTime":"0","endTime":"0","summary":"Mink Therapeutics reported new clinical and translational data on its investigational allo-iNKT cell therapy agenT-797 at the American Thoracic Society International Conference 2026, with the case study also published in Clinical Immunology Communications.The sequential regimen pairing agenT-797 with ImmunityBio’s IL-15 superagonist N-803 was linked to pathogen suppression, signs of lung immune recovery, reduced inflammatory signaling, and activation of tissue repair pathways in a critically ill patient with disseminated Coccidioides infection, ARDS, and hospital-acquired Pseudomonas pneumonia.The patient later transitioned to comfort care due to recurrent cardiac decompensation, with investigators attributing the likely terminal mechanism to acute heart failure rather than cytokine release or infection.The update supports an ongoing randomized Phase 2 trial testing agenT-797 with standard of care versus placebo with standard of care in ICU patients with severe acute lung injury and ac","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDLc2537c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4139","IE00BN0W2T93.GBP","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","LU2095319765.USD","LU0314104364.USD","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","INKT","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636265708","title":"MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2636265708","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636265708?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:07","pubTimestamp":1779289620,"startTime":"0","endTime":"0","summary":"agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved IL","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298712/0/en/MiNK-Therapeutics-Reports-New-Data-on-agenT-797-an-allo-iNKT-Cell-Therapy-at-ATS-2026-Simultaneously-Published-in-Clinical-Immunology-Communications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4139","ATS","INKT","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636107227","title":"MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636107227","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636107227?lang=en_us&edition=fundamental","pubTime":"2026-05-18 23:22","pubTimestamp":1779117720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INKT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 11:22 ET (15:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636012042","title":"Analysts Are Bullish on These Healthcare Stocks: Biofrontera (BFRI), MiNK Therapeutics (INKT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636012042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636012042?lang=en_us&edition=fundamental","pubTime":"2026-05-18 14:30","pubTimestamp":1779085811,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biofrontera (BFRI) and MiNK Therapeutics (INKT) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biofrontera-bfri-mink-therapeutics-inkt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biofrontera-bfri-mink-therapeutics-inkt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BLSG","INKT","BFRI","BK4137","LU0029874061.USD","LU0128526141.USD","BK4581","BK4139","XBI","LABU","BK4585","BK4588","BK4112","BLSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635531970","title":"Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635531970","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635531970?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:47","pubTimestamp":1778881642,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryMink Therapeutics Inc INKT.OQ reported a quarterly adjusted loss of 57 cents per share for the quarter ended Marc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S28F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635894940","title":"MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635894940","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635894940?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:36","pubTimestamp":1778845012,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 18.57 percent increase over losses of $(0.70) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52592441/mink-therapeutics-q1-eps-0-57-beats-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089955","title":"MiNK Therapeutics Q1 FY26 net loss narrows to $2.74 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089955?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:31","pubTimestamp":1778844688,"startTime":"0","endTime":"0","summary":"Mink Therapeutics posted a first-quarter net loss of USD 2.74 million, narrowing from USD 2.77 million a year earlier, while loss per share improved to USD 0.57 from USD 0.70.Cash and cash equivalents fell to USD 9.53 million at March 31, 2026 from USD 13.36 million at end-2025, while cash used in operations rose to USD 1.73 million from USD 1.34 million a year earlier.During the quarter, it repaid about USD 5.2 million tied to the Agenus convertible note and raised about USD 3 million via its at-the-market sales agreement.MiNK initiated a randomized Phase 2 trial of agenT-797 in severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026.CEO Jennifer Buell said the off-the-shelf iNKT therapy is designed for use without lymphodepletion or HLA matching in settings where speed and tolerability matter, including severe acute lung injury and critical illness.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL1fLrLj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","SG9999014005.SGD","IE00B64PRP62.GBP","INKT","AGEN","NDAQ","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635008998","title":"BRIEF-MiNK Therapeutics Q1 EPS USD -0.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2635008998","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635008998?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844647,"startTime":"0","endTime":"0","summary":"BRIEF-MiNK Therapeutics Q1 EPS USD -0.57\n\n\nMay 15 (Reuters) - MiNK Therapeutics Q1 net income USD -2.7 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLXA44347:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635008962","title":"Mink Therapeutics Q1 EPS USD -0.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2635008962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635008962?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLXA44347:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635899440","title":"Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635899440","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635899440?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"-- Randomized Phase 2 trial initiated for agenT-797 in severe acute lung. injury and respiratory distress, with preliminary data expected in the. -- AACR and ASGCT presentations showcase durable survival and. context-dependent iNKT activity in cancer and inflammatory lung disease. -- Non-dilutive collaborations expand MiNK's platform and potentiate. meaningful commercial revenue potential, while preserving focus on lead. Dr. Buell continued, \"What continues to distinguish agenT-797 is both its biology and its practicality. As an off-the-shelf iNKT cell therapy administered without lymphodepletion or HLA matching, agenT-797 is designed for settings where immune dysfunction drives poor outcomes and where speed, tolerability and deployability matter. We believe this is particularly relevant in severe acute lung injury and critical illness, where patients often face a cascade of respiratory failure, secondary infection and organ dysfunction with limited therapeutic options.\". MiNK initiate","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","INKT","BK4139","IBRX","ATS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742965","title":"MiNK Therapeutics initiates agenT-797 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742965","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742965?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:31","pubTimestamp":1778779871,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) and First Lviv Territorial Medical Union announced the initiation of a randomized Phase 2 clinical trial evaluating agenT-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-initiates-agent-797-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-initiates-agent-797-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635711790","title":"Mink Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness","url":"https://stock-news.laohu8.com/highlight/detail?id=2635711790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635711790?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758256,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R0QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089711","title":"Mink Therapeutics Inc: Preliminary Data Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089711?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758256,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R0QD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635714125","title":"MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness","url":"https://stock-news.laohu8.com/highlight/detail?id=2635714125","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635714125?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758200,"startTime":"0","endTime":"0","summary":"Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic respiratory failureStudy initiates in Lviv, Ukraine, in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294797/0/en/MiNK-Therapeutics-and-First-Lviv-Territorial-Medical-Union-Initiate-Randomized-Phase-2-Trial-of-agenT-797-in-Acute-Lung-Injury-and-Critical-Illness.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139","BK4195","TBNK","BK4211","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635733999","title":"Mink Therapeutics Inc  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635733999","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635733999?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:23","pubTimestamp":1778682186,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc  expected to post a loss of77cents a share - Earnings Preview Mink Therapeutics Inc INKT.OQ INKT.O is expected to  show no change in quarterly revenue when it reports  results on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q20A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634154352","title":"Mink Therapeutics data show agenT-797 iNKT cells drive context-dependent immune responses","url":"https://stock-news.laohu8.com/highlight/detail?id=2634154352","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634154352?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:36","pubTimestamp":1778585775,"startTime":"0","endTime":"0","summary":"Mink Therapeutics flagged new clinical data on its off-the-shelf iNKT cell therapy agenT-797, with results scheduled for presentation May 14, 2026 at ASGCT 2026.Across separate studies in solid tumors and acute respiratory distress syndrome, agenT-797 from same donor manufacturing batch produced disease-appropriate immune effects, supporting a single product strategy across oncology and critical care without genetic engineering.Reported outcomes included tumor responses in cancer patients, including a complete metastatic remission in a combination setting, alongside improved survival and pathogen clearance signals in severe ARDS.Company also cited a favorable safety profile in both settings, with immune activation occurring without signs of uncontrolled systemic inflammatory toxicity.Data were positioned to support a move into randomized Phase 2 testing in acute lung injury under trial C-1300-02, with preliminary readout expected in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4dHN0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4588","SG9999014021.USD","BK4585","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","INKT","NDAQ","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634373216","title":"MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634373216","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634373216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:35","pubTimestamp":1778585700,"startTime":"0","endTime":"0","summary":"iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292728/0/en/MiNK-Therapeutics-Presents-Clinical-Evidence-That-a-Single-Off-the-Shelf-iNKT-Cell-Product-Drives-Context-Dependent-Immune-Responses-at-ASGCT-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634829762","title":"Mink Therapeutics Inc  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634829762","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634829762?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:32","pubTimestamp":1778506329,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc  expected to post a loss of77cents a share - Earnings Preview Mink Therapeutics Inc INKT.OQ INKT.O is expected to  show no change in quarterly revenue when it reports  results on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O1GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634462580","title":"Mink Therapeutics to report Q1 results, host conference call and webcast May 15","url":"https://stock-news.laohu8.com/highlight/detail?id=2634462580","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634462580?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:30","pubTimestamp":1778272240,"startTime":"0","endTime":"0","summary":"Mink Therapeutics schedules first-quarter 2026 results release for May 15, 2026, before U.S. market open.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL5N4872:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","LU2210149790.SGD","BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014021.USD","BK4588","IE00BGHQF748.EUR","INKT","NDAQ","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014039.USD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minktherapeutics.com;investor.minktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0299},{"period":"1month","weight":-0.1638},{"period":"3month","weight":-0.042},{"period":"6month","weight":0.0152},{"period":"1year","weight":0.486},{"period":"ytd","weight":-0.0386}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0459},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.2503},{"period":"ytd","weight":0.087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.041395},{"month":2,"riseRate":0.2,"avgChangeRate":-0.047548},{"month":3,"riseRate":0,"avgChangeRate":-0.079206},{"month":4,"riseRate":0.4,"avgChangeRate":0.010238},{"month":5,"riseRate":0,"avgChangeRate":-0.104588},{"month":6,"riseRate":0.5,"avgChangeRate":0.033071},{"month":7,"riseRate":0.25,"avgChangeRate":0.215487},{"month":8,"riseRate":0.25,"avgChangeRate":0.146012},{"month":9,"riseRate":0,"avgChangeRate":-0.132506},{"month":10,"riseRate":0.5,"avgChangeRate":-0.021174},{"month":11,"riseRate":0.6,"avgChangeRate":-0.066406},{"month":12,"riseRate":0.4,"avgChangeRate":-0.119867}],"exchange":"NASDAQ","name":"MiNK Therapeutics, Inc.","nameEN":"MiNK Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MiNK Therapeutics, Inc.,INKT,MiNK Therapeutics, Inc.股票,MiNK Therapeutics, Inc.股票老虎,MiNK Therapeutics, Inc.股票老虎国际,MiNK Therapeutics, Inc.行情,MiNK Therapeutics, Inc.股票行情,MiNK Therapeutics, Inc.股价,MiNK Therapeutics, Inc.股市,MiNK Therapeutics, Inc.股票价格,MiNK Therapeutics, Inc.股票交易,MiNK Therapeutics, Inc.股票购买,MiNK Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}